Protagonist Therapeutics
PTGX
132 hedge funds and large institutions have $821M invested in Protagonist Therapeutics in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 57 increasing their positions, 35 reducing their positions, and 31 closing their positions.
71% more call options, than puts
Call options by funds: $25.9M | Put options by funds: $15.1M
63% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 35
4% less funds holding
Funds holding: 138 → 132 (-6)
4.92% less ownership
Funds ownership: 102.51% → 97.59% (-4.9%)
16% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 31
62% less capital invested
Capital invested by funds: $2.16B → $821M (-$1.34B)
80% less funds holding in top 10
Funds holding in top 10: 10 → 2 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$138M |
| 2 |
AG
Artal Group
Luxembourg
|
+$64M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$61.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$23.8M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$155M |
| 2 |
RI
RTW Investments
New York
|
-$74.8M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$37.9M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$26.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.6M |
PTGX Hedge Fund Activity: Q3 2021 in Review
132 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2021, worth a combined $821M — down 62% from $2.16B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of PTGX and 26 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 57 added.
The largest buyer was Point72 Asset Management, adding an estimated $138M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $155M sold.
- 132 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2021, down from 138 in Q2 2021.
- Funds reported $821M of Protagonist Therapeutics stock for Q3 2021, down 62% quarter-over-quarter.
- 26 funds opened new Protagonist Therapeutics positions in Q3 2021 and 31 closed out, a net change of -5 holders.
- The largest Protagonist Therapeutics buyer in Q3 2021 was Point72 Asset Management, an estimated $138M added.
- The largest Protagonist Therapeutics seller in Q3 2021 was Consonance Capital Management, an estimated $155M sold.
Based on aggregated 13F filings for Q3 2021.